Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • kgulukota
    Member
    • Oct 2011
    • 30

    Just how much is genetic related anyway?

    Roberts et al have analyzed large cohorts of monozygotic twins to try and determine the theoretical limits of how useful genomic sequencing can be.

    New DNA sequencing methods will soon make it possible to identify all germline variants in any individual at a reasonable cost. However, the ability of whole-genome sequencing to predict predisposition to common diseases in the general population is unknown. To estimate this predictive capacity, we …


    Amid the breathless anticipation about the $1000 genome and beyond, it is sobering to remember what we knew all along: there is PLENTY of environmental effects on how we turn out.

    Even if we could sequence and analyze genomes for negligible cost, there still remains a significant hurdle: lack of knowledge about what genetic variation really means for phenotype.

    I guess we should be happy: our jobs are safe for the foreseeable future.
    Kamalakar Gulukota,
    Director,
    Center for Bioinformatics and Computational Biology
    NorthShore University Health System, [email protected]
  • Joann
    Senior Member
    • Oct 2008
    • 230

    #2
    Hi Gulu,

    I think newborn screening applications (for detecting and treating the many treatable genetic diseases at birth) will be a good start. US state public health departments are recognizing the potential of switching from gene panels to whole genome sequencing.

    Comment

    Latest Articles

    Collapse

    • mylaser
      Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by mylaser
      Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
      If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
      This guide explains everything you need to know about...
      Yesterday, 01:13 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-09-2026, 10:04 AM
    0 responses
    20 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-08-2026, 10:08 AM
    0 responses
    12 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-07-2026, 11:05 AM
    0 responses
    30 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-02-2026, 11:08 AM
    0 responses
    31 views
    0 reactions
    Last Post SEQadmin2  
    Working...